Please login to the form below

Not currently logged in
Email:
Password:

Acthar

This page shows the latest Acthar news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt files for bankruptcy protection in the US

Mallinckrodt files for bankruptcy protection in the US

In addition to resolving matters relating to the opioid litigation, the bankruptcy filing will also resolve matters related to Mallinckrodt’s Acthar (corticotropin) Gel. ... Mallinckrodt agreed to pay $260m over seven years to the federal government

Latest news

  • US piles pressure on Mallinckrodt over alleged Acthar fraud US piles pressure on Mallinckrodt over alleged Acthar fraud

    system. The complainant says that Mallinckrodt understated the rebates it was due to pay Medicaid over a period in which it raised the price of its $40, 000-per-vial Acthar ... The NDA approval was awarded to Acthar’s earlier owner Questcor, which was

  • Mallinckrodt offloads CDMO for $250m Mallinckrodt offloads CDMO for $250m

    This will likely include the active ingredient for Acthar, which the pharma company has faced criticism for due to its inflated pricing. ... US health insurer Humana recently filed a lawsuit against Mallinckrodt, alleging that it overpaid $700m for Acthar

  • Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose' Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'

    The nonprofit allegedly used money from Mallinckrodt to provide patient assistance funds solely for Acthar. ... Over the decades, other drugs superseded Acthar in many, but not all, indications, culminating in Aventis Pharmaceuticals selling the asset to

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    Mallinckrodt is trying to reduce its reliance on cash cow product Acthar (corticotropin) for infantile spasms and multiple sclerosis, which brought in sales of almost $309m in the third quarter of ... Acthar’s slowdown has been attributed by the

  • Ireland's Mallinckrodt buys US regenerative medicine firm Ireland's Mallinckrodt buys US regenerative medicine firm

    Ikaria. In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses, proteinuria

  • Pharma deals during February 2014 Pharma deals during February 2014

    Questor and Retrophin are is now in litigation over two synthetic versions of Acthar (ACTH), a corticotropin with 19 indications, many in rare diseases including infantile spasms, MS, nephrology, and rheumatology.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Questcor appoints SVP corporate strategic development Questcor appoints SVP corporate strategic development

    These moves could see it expand outside the US with its lead product HP Acthar Gel  (repository corticotropin injection), an injectable drug, which is approved by the FDA in several indications ... Development programmes that complement Acthar are also

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....